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Campylobacteriosis is the leading zoonosis in the European Union with the majority
of cases attributed to Campylobacter jejuni. Although the disease is usually self-
limiting, some severe cases need to be treated with antibiotics, primarily macrolides
and quinolones. However, the resistance to the latter is reaching alarming levels in
most of the EU countries. To shed light on the expansion of antibiotic resistance in
central Europe, we have investigated genetic similarity across 178 ciprofloxacin-resistant
C. jejuni mostly isolated in Slovenia, Austria and Germany. We performed comparative
genetic similarity analyses using allelic types of seven multilocus sequence typing
housekeeping genes, and single nucleotide polymorphisms of a quinolone resistance
determining region located within the DNA gyrase subunit A gene. This analysis revealed
high genetic similarity of isolates from clonal complex ST-21 that carry gyrA allelic type 1
in all three of these central-European countries, suggesting these ciprofloxacin resistant
isolates arose from a recent common ancestor and are spread clonally.
Keywords: Campylobacter jejuni, ciprofloxacin resistance, multilocus sequence typing, gyrA, QRDR, resistance
expansion
INTRODUCTION
Campylobacteriosis is the leading zoonosis in the European Union (EU), with the majority of cases
attributed to Campylobacter jejuni (EFSA, 2015). Severe or prolonged cases of campylobacteriosis
are conventionally treated with antibiotics from the macrolide (erythromycin) and quinolone
(ciproﬂoxacin) classes. While macrolide resistance is successfully retained at low levels (human
isolates EU average, 1.5%), some EU Member States report up to 91.5% prevalence of quinolone
resistance (EFSA, 2015). The resistance prevalence among C. jejuni from humans was 64.1 and
63.0% in Slovenia and Austria in 2013, respectively (EFSA, 2015). The main mechanism that
confers high-level resistance to ciproﬂoxacin in Campylobacter is the occurrence of the Thre86Ile
point mutation in the quinolone-resistance-determining region (QRDR) of the gene that encodes
DNA gyrase subunit A (gyrA), although other mutations within gyrA, as well as enhanced
Frontiers in Microbiology | www.frontiersin.org 1 October 2015 | Volume 6 | Article 1169
Kovacˇ et al. Expansion of ciprofloxacin-resistant C. jejuni
eﬄux activity can contribute to development of ciproﬂoxacin
resistance (Wieczorek and Osek, 2013). The Thre86Ile resistant
mutants have also been demonstrated to have increased chicken
colonization ﬁtness (Luo et al., 2005) in certain genetic
backgrounds, giving them an advantage over susceptible strains.
In other genetic backgrounds, the advantage was not observed
(Zeitouni and Kempf, 2011). The resistance to quinolones is
especially problematic due to their therapeutic use in human
and veterinary medicine, including in food production animals,
which allows for transmission of antibiotic resistance along the
food-production chain to humans (EMA/ESVAC, 2011).
Several studies have reported the resistance and genotype
data that demonstrated increased prevalence of resistance in
certain genotypes in diﬀerent geographical regions (Kinana
et al., 2006: D’lima et al., 2007; Gu et al., 2009; Habib et al.,
2009; Wirz et al., 2010; Stone et al., 2013; Wu et al., 2014;
Jonas et al., 2015). Furthermore, associations of particular
multilocus sequence typing (MLST) clonal complexes with
resistance were suggestive of clonal expansion of ciproﬂoxacin
resistance in Slovenia, the UK and Switzerland (Cody et al.,
2012; Kittl et al., 2013; Wimalarathna et al., 2013; Kovacˇ et al.,
2014).
To provide better insight into the epidemiology of C. jejuni
antibiotic resistance in central Europe, we performed a
comparative genetic similarity analysis of 178 ciproﬂoxacin-
resistant C. jejuni strains isolated in Slovenia, Austria and
Germany. We used standard MLST coupled with single
nucleotide polymorphism (SNP) analysis of the QRDR of gyrA
to investigate the genetic relatedness of ciproﬂoxacin resistant
C. jejuni isolates and shed light on the nature of their expansion
in these three central-European countries.
MATERIALS AND METHODS
Bacterial Strains
The 178 ciproﬂoxacin resistant C. jejuni strains included in this
study were isolated from poultry, cattle, chicken meat, cow milk,
surface water, dog, strawberry, a zoo animal, and human stools
in central Europe (Slovenia, Austria, Germany); two isolates
were obtained from the southern Balkan region (Serbia, Bosnia,
and Herzegovina) (Supplementary Table S1). The strains were
isolated between 2001 and 2013 according to ISO10272, as part
of national monitoring of retail meat and production animals,
human clinical cases, and from other national and EU research
projects.
Bacterial Growth Conditions and DNA
Extraction
Stocks of C. jejuni isolates were stored at −80◦C and grown
on selective Karmali agar (Oxoid, Hampsire, UK) for 24 h at
42◦C under microaerobic conditions (5% O2, 10% CO2, in N2).
DNA used for molecular species conﬁrmation and MLST typing
was extracted with PrepMan Ultra Sample Preparation Reagent
(Applied Biosystems, Foster City, CA, USA), according to the
manufacturer protocol. DNA was used for C. jejuni species
conﬁrmation according to Wang et al. (2002), and ampliﬁcation
of MLST housekeeping genes and gyrA QRDR. All primers used
in this study are listed in Supplementary Table S2.
Antibiotic Resistance
Resistances to ciproﬂoxacin (0.06–4 mg/l), chloramphenicol
(2–32 mg/l), erythromycin (0.5–32 mg/l), gentamicin (0.12–
16 mg/l), streptomycin (1–16 mg/l) and tetracycline (0.25–
16 mg/l) were determined by broth microdilution using Eucamp
microtitre plates (Sensititre, Thermo Fischer Scientiﬁc) by
following manufacturers’ instructions. The reference strain
ATCC 33560, which is susceptible to all seven tested antibiotics
was used as a quality control. The minimum inhibitory
concentration (MIC) cut-oﬀs as recommended by EFSA
(2015) were used to identify the resistant phenotypes. Brieﬂy,
isolates with MICs of ciproﬂoxacin >0.5 mg/l, chloramphenicol
>16 mg/l, erythromycin >4 mg/l, gentamicin >2 mg/l,
streptomycin >4 mg/l, and tetracycline >1 mg/l were identiﬁed
as resistant. The MICs and resistance breakpoints are available in
Supplementary Table S1.
Multilocus Sequence Typing
Multilocus sequence typing was carried out according to the
established C. jejuni MLST scheme, with primers listed in
Supplementary Table S2 (Dingle et al., 2001). Sequences
(Sanger sequencing; Macrogen, South Korea) were used for
the identiﬁcation of MLST proﬁles using Bionumerics 7.1 with
the MLST plugin (Applied Maths NV, Sint-Martens-Latem,
Belgium). The MLST proﬁles identiﬁed in this study have
been deposited in the PubMLST database http://pubmlst.org/
campylobacter (Jolley and Maiden, 2010). The PubMLST IDs are
available in Supplementary Table S1. The minimum-spanning
tree (Figure 1) demonstrating the genetic similarity among
strains was built using MLST allele variants in Bionumerics
version 7.1 (Applied Maths).
Quinolone-Resistance-Determining
Region
The QRDR of gyrA of 178 ciproﬂoxacin-resistant C. jejuni
isolates was ampliﬁed using primers GZgyrA5 and GZgyrA6 in
a single PCR, and Sanger sequenced using primers GZgyrA7
and GZgyrA8 (Zirnstein et al., 1999; Supplementary Table S2).
The 389-bp-long QRDR sequences spanning from nucleotide
positions 92 to 481 within gyrA were aligned in MEGA
V6.0 (Tamura et al., 2013) to identify the unique variants of
gyrA. Every sequence with new SNP (synonymous or non-
synonymous) observed was designated a new gyrA allelic type
number. The conserved region of gyrA outside of QRDR was
previously used by others for epidemiological investigation
of C. jejuni and C. coli host speciﬁcity (Ragimbeau et al.,
2014). Here we have investigated the QRDR region, as its
sequence diversity is directly associated with ciproﬂoxacin
resistance.
Statistical Analysis
Statistical associations between gyrA types and MLST clonal
complexes, and between gyrA+MLST types and multidrug
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FIGURE 1 | Genetic similarity of the 178 analyzed Campylobacter jejuni
isolates. The minimum spanning tree was constructed based on the
multilocus sequence typing (MLST) allelic profiles using Bionumerics, version
7.1. The genotype specific for clonal complex ST-21 + gyrA 1 is presented in
dark red and for gyrA 1 in combination with a clonal complex other than ST-21
is in light red; the genotype for clonal complex ST-353 + gyrA 13 is in dark
blue; and for gyrA 13 in combination with a clonal complex other than ST-353
is in light blue. The figure demonstrates higher similarity of isolates carrying
gyrA allelic type 1, which cluster within clonal complex ST-21 (dark red),
compared to isolates carrying gyrA 13, which are found within clonal complex
ST-353 (dark blue), but are also dispersed among other clonal complexes
(light blue).
resistance were carried out using Fischer’s exact tests in R, version
3.1.2, with the statistical relevance cut-oﬀ set at p < 0.01 (R Core
Team, 2014).
RESULTS
Analyses of antibiotic co-resistance (multidrug resistance)
were carried out on the isolates, with the MICs determined
for all seven of the antibiotics tested (n = 163). The
MICs of ciproﬂoxacin-resistant isolates ranged from 2 to
over 4 mg/l, conﬁrming a high-level resistance in all of
them (resistance MIC cut-oﬀ is >0.5 mg/l). Among them,
76 (46.6%) isolates were either resistant to ciproﬂoxacin
only (n = 4) or were cross-resistant to nalidixic acid
(n = 72). The MICs of nalidixic acid ranged from 32 to
over 46 mg/ml. Seventy-six isolates (46.6%) were co-resistant
to ciproﬂoxacin and another antibiotic from a diﬀerent class,
which was exclusively tetracycline. MICs of tetracycline were
ranging from 2 to over 16 mg/l, however most of the
isolates (n = 61; 80.3%) were resistant to concentrations
16 mg/l or higher. Seven of the ciproﬂoxacin-resistant isolates
(4.3%) were additionally resistant to either streptomycin
and erythromycin, or streptomycin and tetracycline. Three
isolates (1.8%) were resistant to antibiotics from four diﬀerent
classes, and a single isolate (0.6%) was resistant to antibiotics
from ﬁve diﬀerent classes (Supplementary Table S1). As
demonstrated in Figure 2, higher proportion of resistance
only to quinolone (1R) antibiotics was observed among
isolates from poultry source (n = 50; 34.9%, p < 0.001),
compared to isolates of bovine origin, where resistance to
two classes of antibiotics (quinolones and tetracyclines – 2R)
was prevailing (n = 20; 74.0%; p = 0.003). However, these
diﬀerences arise mostly due to the high proportion of 1R
among Slovenian poultry isolates (n = 33; 55%), compared to
Austrian (n = 8; 17.4%) and German (n = 9; 33.3%), suggesting
divergent antibiotic treatment practices in Slovenia, Austria, and
Germany.
We identiﬁed 67 diﬀerent MLST sequence types (STs) that
were distributed among 21 clonal complexes (Table 1). Twenty
isolates could not be assigned to any of the existing clonal
complexes. Novel variants of alleles aspA (aspA 387), glyA
FIGURE 2 | Co-existence of quinolone resistance with resistances to
other classes of antibiotics among isolates from bovine (n = 27) and
poultry (n = 91) source. 1R, 2R, 3R, 4R, 5R, resistance to quinolone alone
(1R), and to antibiotics from one, two (exclusively quinolone and tetracycline),
three, four and five other classes, respectively. Only isolates with resistance
determined for all seven antibiotics tested ( n = 163) were included in the
analysis.
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TABLE 1 | The distribution of ciprofloxacin-resistant Campylobacter jejuni isolates, originating from different countries among MLST clonal complexes.
Austria Germany Slovenia Serbia Bosnia and Herzegovina SUM
ST-21 complex 22 15 24 61
ST-353 complex 7 3 15 1 26
UA 10 1 9 20
ST-354 complex 2 8 10
ST-206 complex 5 1 3 9
ST-464 complex 6 1 1 8
ST-257 complex 4 1 1 6
ST-45 complex 4 2 6
ST-443 complex 4 1 5
ST-48 complex 2 1 2 5
ST-52 complex 1 4 5
ST-574 complex 4 4
ST-22 complex 1 1 2
ST-607 complex 1 1 2
ST-658 complex 2 2
ST-1034 complex 1 1
ST-283 complex 1 1
ST-362 complex 1 1
ST-42 complex 1 1
ST-49 complex 1 1
ST-692 complex 1 1
ST-828 complex 1 1
SUM 70 30 76 1 1 178
(599), tkt (578), and uncA (458) were identiﬁed, along with
the deﬁnition of their novel corresponding STs: ST 7514, ST
7517, ST 7516, and ST 7515, respectively. One new ST, ST 7506,
was identiﬁed as a novel combination of previously reported
allele types, according to the information in the PubMLST
database.
Sequence type 50 (clonal complex ST-21) was the most
prevalent ST that was common to all three countries, Austria
(n = 12), Slovenia (n = 12) and Germany (n = 3). The
second-most frequent ST among the Slovenian isolates was ST
5205 (clonal complex ST-353) (n = 11), which was identiﬁed
for the ﬁrst time in our previous study (Kovacˇ et al., 2014)
and has been so far reported only for Slovenian (n = 11)
and Austrian (n = 1) isolates, according to the PubMLST
database (accessed on 20 June 2015). The most-prevalent clonal
complex in all three of these countries was ST-21, with 24
representatives in Slovenia, 22 in Austria, and 15 in Germany,
followed by ST-353, with 15 and seven representatives in Slovenia
and Austria, respectively, and ST-45, with four representatives
in Germany (Supplementary Table S1). Both, ST-21 and ST-
353 were highly represented by chicken and human isolates,
but no bovine isolate was assigned to ST-353. The 64.5%
(n = 20; p < 0.001) of bovine isolates carried gyrA type 1,
while 59.8% (n = 49, p < 0.001) of chicken isolates carried gyrA
type 13.
The comparative analysis of the 389-bp-long QRDR
sequences revealed 15 diﬀerent gyrA allelic types with variations
on 25 nucleotide sites (Supplementary Table S1; GenBank
KP794628-KP794805). The sequences were checked for presence
of previously reported resistance-conferring mutations on
nucleotide positions 210, 255, 258, 270, and 312 (according to
full-length gyrA), which corresponded to amino acids Ala70,
Asp85, Thr86, Asp90, and Pro104 (Wieczorek and Osek,
2013). A total of 171 isolates carried the main resistance-
conferring mutation Thr86Ile. This mutation was not detected
in seven isolates, which still exhibited high level resistance to
ciproﬂoxacin (MICs 2 to over 4 mg/l), possibly due to enhanced
eﬄux activity. The gyrA types identiﬁed in isolates lacking
the Thr86Ile mutation were gyrA 7, 8, 9, and 10. None of the
isolates analyzed carried the alternative resistance-conferring
mutations at amino-acid positions 70, 85, or 90, however ﬁve of
the isolates had the Pro104Thr mutation. Pro104Thr is a newly
identiﬁed mutation, as only Pro104Ser has been reported so
far (Wieczorek and Osek, 2013). Pro104Thr was found in four
strains that were isolated in Austria (08/000367, MRC-09/00280,
MRC-10/00374, MRC-11/00224), and in a single strain isolated
in Germany (Bfr-CA-10467) (Supplementary Table S1). All
of the isolates with Pro104Thr mutation possessed the gyrA
type 6.
The most prevalent gyrA STs were gyrA type 13 (n = 86) and
gyrA type 1 (n = 65), with the remaining gyrA STs represented
by only up to ﬁve isolates. The isolates with gyrA type 13
were distributed among 14 clonal complexes, and 26.7% of
these isolates were assigned to ST-353 (ST-353 + gyrA 13;
p < 0.001). On the other hand, isolates with gyrA type 1
were distributed among eight diﬀerent clonal complexes, with
80.0% of these isolates clustering in ST-21 (ST-21 + gyrA
1; p < 0.001). Sequence analysis revealed closer relationships
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between isolates carrying gyrA type 1, which mostly belonged
to clonal complex 21 (ST-21 + gyrA type 1), compared
to isolates carrying gyrA type 13 (Figure 1). Both of these
gyrA types were found in isolates from Slovenia, Austria, and
Germany.
Isolates with genotype ST-353 + gyrA 13 were in most
cases (n = 13; 61.9%; p < 0.001) resistant only to ciproﬂoxacin
or to ciproﬂoxacin and nalidixic acid. Similar numbers,
but lower proportions, of solely ciproﬂoxacin resistant
isolates (n = 18; 39.1%; p = 0.2244) were observed also
for genotype ST-21 + gyrA 1. A higher proportion of
isolates with genotype ST-21 + gyrA 1 were resistant to
two classes of antibiotics (n = 25; 54.3%; p = 0.222),
than of isolates with genotype ST-353 + gyrA 13 (n = 5;
23.8%, p = 0.035). The proportions of isolates resistant to
three antibiotics from diﬀerent classes were low, both for
ST-353 + gyrA 13 (n = 3; 14.3%) and for ST-21 + gyrA
1 (n = 1; 2.2%). Isolates that showed resistance to four
and ﬁve antibiotics were represented only by genotype
ST-21 + gyrA 1.
DISCUSSION
The current antibiotic-resistance problem among zoonotic
agents demonstrates the need for improvements to resistance
management policy. The EU ban on antibiotic use for growth
promotion in animal husbandry was a step forward (European
Commission, 2011). However, the extensive amounts of clinically
important antibiotics that are applied for treatment and
control of pathogens in food-production animals still support
the spread and persistence of resistant bacterial populations
in the food production chain, and therefore compromise
eﬃcient treatment of human infections (EMA/ESVAC,
2014).
Although the ban on the use of antibiotics in food
animals may not produce the immediate targeted eﬀects,
studies from several countries that have established such
policies have provided evidence for its sustainability, in
terms of decreasing the prevalence of antibiotic resistance
(Norström et al., 2006; Nelson et al., 2007; Skjøt-Rasmussen
et al., 2009). Nevertheless, the implications of such policies
and risk analyses for the expansion of antibiotic resistance
through the international trade in chicken meat have not been
evaluated to date, although such investigations are urgently
needed.
Here, we have investigated the genetic similarity of
ciproﬂoxacin-resistant strains isolated from the environment,
animals, food and human in three central-European countries
over the last 12 years to gain knowledge about their distribution
among diﬀerent genotypes that could potentially explain the
mechanisms driving the increase in ciproﬂoxacin resistance
prevalence in C. jejuni. We have found that resistance to
ciproﬂoxacin alone (1R) is more frequently observed among
poultry isolates, compared to bovine isolates where resistance to
ciproﬂoxacin and tetracycline (2R) is more common. Although
the associations were statistically signiﬁcant according to
Fischer’s exact test, the observations are biased, as substantially
higher proportion of 1R isolates originates from Slovenia,
compared to Austria and Germany. According to an opinion
of Slovenian veterinary expert familiar with the ﬁeld use of
antibiotics in poultry, this can be explained with preferential use
of enroﬂoxacin, rather than tetracyclines for poultry treatment
in Slovenia. Main reason for that is the shorter withdrawal
period and less problems with antibiotic precipitation in
water.
Ciproﬂoxacin-resistant isolates clustered in two groups
of high genetic similarity, as inferred based on MLST
and SNP analyses of the QRDR. These two groups
comprised isolates from MLST clonal complex ST-353
with gyrA type 13 and isolates from clonal complex ST-
21 with gyrA type 1. While isolates from both of these
MLST clonal complexes were signiﬁcantly associated with
their corresponding gyrA types, the sequence similarity
analysis revealed closer relationships between isolates
carrying gyrA type 1. Isolates with gyrA type 13 were
widely dispersed also in clonal complexes other than
ST-353, while isolates with gyrA type 1 belonged almost
exclusively to MLST clonal complex 21, indicating
they have expanded from a recent common ancestor.
Furthermore, strains isolated from all three countries
over several diﬀerent years can be found within the
group.
We have found 17 STs appearing between animal, as
well as human isolates. Five of those (STs 50, 21, 104,
5205, and 572) were found more than once among
human isolates. Of those, ST 50, 21, and 104 belong to
clonal complex ST-21, ST 5205 to clonal complex ST-
353, while 572 was unassigned. These ﬁndings suggest
epidemiological linkage between animal and human
isolates from clonal complexes ST-21 and ST-353, which
also had the highest accumulation of ciproﬂoxacin resistant
isolates.
The ST-21, and in particular ST 50 were highly
represented among our set of ciproﬂoxacin resistant
isolates, nevertheless previous studies in other
geographical regions had not found signiﬁcant associations
between this genotype and quinolone resistance or
susceptibility (Cody et al., 2012; Kittl et al., 2013).
On the other hand, they have found ST 464 and
ST 45 to be signiﬁcantly associated with quinolone
resistance, and susceptibility, respectively (Cody et al.,
2012; Kittl et al., 2013). These two STs, however,
were not identiﬁed frequently enough among our
ciproﬂoxacin resistant isolates, to draw statistically relevant
conclusions.
It is becoming increasingly evident that the global escalation
of quinolone resistance in Campylobacter is associated with
spreading of certain resistant genotypes (Cody et al., 2012;
Kittl et al., 2013; Wimalarathna et al., 2013; Kovacˇ et al.,
2014), which may be driven by globalization in the poultry
trade (AVEC, 2014) and/or of travel. Our ﬁndings suggest
that the ciproﬂoxacin resistance is expanding with widespread
C. jejuni clonal complex ST-21 in central Europe. Further
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research focused on identifying the genetic traits other than
antibiotic resistance determinants that may facilitate this process
is needed, in order to better understand the antibiotic resistance
epidemiology, and implement successful resistance control
measures.
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